Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique β-lactam and a β-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of SUL-DUR, discussing its unique features and role in treating infections caused by CRAB pathogens.
CITATION STYLE
Watkins, R. R., & Bonomo, R. A. (2023). Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections. Clinical Infectious Diseases, 76, S163–S165. https://doi.org/10.1093/cid/ciad093
Mendeley helps you to discover research relevant for your work.